Caredx Inc buy stratec
Summary
This prediction ended on 05.11.21 with a price of €41.60. The BUY prediction by stratec finished with a performance of 15.62%. stratec has 50% into this predictionCareDx is a publicly traded biotechnology company that specializes in providing innovative transplant solutions for patients suffering from various diseases. The company has developed a range of diagnostic solutions that help doctors monitor the health of organ transplant recipients, including tests that can detect early signs of organ rejection. CareDx has a strong track record of developing cutting-edge medical technologies and working with leading healthcare providers to improve patient outcomes. As a publicly-listed company, CareDx has a diverse shareholder base and is subject to the scrutiny of regulatory bodies, providing transparency and accountability to investors.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Caredx Inc | 18.971% | 18.971% | 81.571% | -75.229% |
iShares Core DAX® | -0.543% | 1.491% | 13.638% | 16.760% |
iShares Nasdaq 100 | -2.696% | -1.235% | 31.879% | 45.155% |
iShares Nikkei 225® | -2.863% | 2.491% | 12.078% | 7.840% |
iShares S&P 500 | -1.105% | 0.013% | 26.888% | 43.056% |
Comments by stratec for this prediction
In the thread Caredx Inc diskutieren
CareDX is a "best in class growth story" in the transplant diagnostic space.
CareDx ist mit einem Produkt am Markt, mit dem sich vorhersagen lässt, ob Nierentransplantationen "abgelehnt" werden. Man geht davon aus, dass die Anordnung der Exekutive der Trump-Administration das jährliche Wachstum der Anzahl der abgeschlossenen Organtransplantationen um 12-15% steigern wird.
In the thread Trading Caredx Inc